Who
Jennifer Tousignant
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Viridian Therapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $838K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Feb 2024
- Last trade
- 19 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K4,212 at $24.50 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | $144K10,000 at $14.41 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Sold | $245K10,000 at $24.50 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K4,212 at $24.50 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | $144K10,000 at $14.41 | filing |
| 19 Aug 2026filed 20 Aug 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Sold | $245K10,000 at $24.50 | filing |
| 3 Mar 2026filed 9 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $51K1,675 at $30.19 | filing |
| 3 Mar 2026filed 9 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $51K1,675 at $30.19 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,169 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $51K1,724 at $29.32 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,169 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,169 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,169 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $51K1,724 at $29.32 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,300 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,300 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,850 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,850 at $0.00 | filing |
News
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% – Here's WhyVRDN · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Jennifer Tousignant; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.